Skip to content
Biodatica
Start free

Pelage Pharmaceuticals, Inc.

LOS ANGELES, CA · also filed as None

OncologyPhase II
Compare Sign in to watch

What changed

Study registered, no phase assigned: A Stepped Care Approach to Treating Dental Fear

2mo agoTrial registeredMay 15, 2026Source filing (opens the source filing in a new tab)

Momentum

86no change

Momentum 86 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~67months

The last disclosed raise still models out past a year.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,772 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D · $120M

    Nov 24, 2025

    Pelage Pharmaceuticals, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0001982875-25-000002 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Aug 9, 2024

    Dental Fear · ACTIVE_NOT_RECRUITING · sponsor: New York University · Virtual Reality Exposure for Dental Fear

    ClinicalTrials.gov · NCT06494176 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jun 5, 2024

    Androgenetic Alopecia · COMPLETED · sponsor: Pelage Pharmaceuticals, Inc. · Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

    ClinicalTrials.gov · NCT06393452 (opens the source filing in a new tab)

  4. Grant

    R01 · $447k · non-dilutive

    Apr 11, 2024

    UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LOWRY, WILLIAM E · NIAMS · award ends Mar 31, 2029 · Metabolic Control of Hair Follicle Stem Cell Homeostasis and Tumorigenesis

    NIH RePORTER · NIH RePORTER 11330485 (opens the source filing in a new tab)

  5. Trial

    NA registered

    Sep 11, 2023

    Dental Fear · RECRUITING · sponsor: New York University · A Stepped Care Approach to Treating Dental Fear

    ClinicalTrials.gov · NCT06024395 (opens the source filing in a new tab)

  6. Grant

    P30 · $264k · non-dilutive

    Dec 1, 1996

    UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LOWRY, WILLIAM E · NCI · award ends Mar 31, 2030 · Cancer Research Training and Education Coordination (CRTEC)

    NIH RePORTER · NIH RePORTER 11373194 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources